Compare AbCellera Biologics Inc (ABCL) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.8. Which is the better fit depends on your goals.
| ABCL | VOOG | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $85.11 |
52-Week Low | $2.78 | $65.32 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VOOG trades at $82.41, up 1.22% today, with a bullish technical outlook from moving averages but neutral oscillators. The ETF completed a 1:6 stock split in April 2026 to enhance accessibility. Recent news highlights its low 0.07% expense ratio and strong long-term growth focus on S&P 500 constituents, though short interest rose significantly in March 2026.
Outlook remains positive due to cost efficiency and growth stock exposure, but risks include tech sector volatility and high valuations. Investors benefit from diversification but should monitor market sentiment shifts amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
